secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001437749-26-012488
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals appoints Judith Matthews as CFO effective June 1, 2026
---------------------------------------------------------------------------

- Judith Matthews will become CFO on June 1, 2026, succeeding James Gruber who remains through May 31 then six-month consulting.
- Annual base salary of $440,000, target bonus 45% of salary, one-time option for 37,000 shares vesting over 4 years.
- Matthews was previously CFO of Iterum Therapeutics (2015-2026) and VP Finance at Durata Therapeutics.
- Gruber to provide transition support via six-month consulting agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/0001437749-26-012488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926012488/eton20260413_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer